

CNB NEWS RELEASE

30 Apr 2014

LISTING OF FIFTH SCHEDULE DRUGS TO THE FIRST SCHEDULE OF THE MISUSE OF DRUGS ACT WITH EFFECT FROM 1 MAY 2014

With effect from 1 May 2014, the Central Narcotics Bureau (CNB) will be listing all the psychoactive substances currently in the Fifth Schedule of the Misuse of Drugs Act (MDA), in the First Schedule of the same Act. This would mean that these substances would be re-classified as Class A controlled drugs (see [Annex A](#) for the list of Fifth Schedule drugs that will be shifted to the First Schedule).

2 At the same time, a new list of substances will be placed in the Fifth Schedule of the MDA. The new list of substances on the Fifth Schedule is at [Annex B](#).

BACKGROUND & RATIONALE

3 New psychoactive substances (NPS) are today being developed very rapidly across the globe. The Fifth Schedule of the MDA was enacted on 1 May 2013 to allow CNB to control and prevent the proliferation of NPS. NPS can be temporarily listed in the Fifth Schedule for up to 12 months, with a possibility of extension for another 12 months. The Fifth Schedule enables CNB to seize these NPS so that the circulation of such substances can be restricted while research and industry consultation are conducted. These processes are necessary before a substance is classified as a controlled drug. However, the trafficking, manufacture, import, export, possession or consumption of any substance which is temporarily listed in the Fifth Schedule will not constitute an offence under the MDA, until that substance is removed from the Fifth Schedule and is subsequently listed as a controlled drug in the First Schedule whereupon all these offences will apply.

4 Most of these new psychoactive substances are produced by introducing slight modifications to the chemical structures of controlled drugs. Many of these addictive substances have effects similar to other Class A drugs such as cannabis, cocaine, MDMA ('Ecstasy') and LSD (lysergamide); and their abuse have been linked to adverse physical and psychological reactions, including paranoia, seizures, hallucinations, and even death. Based on the United Nations Office on Drugs and Crime (UNODC) World Drug Report 2013, many NPS are being used as substitutes for controlled drugs, often being touted as "legal highs" that can be abused without fear of enforcement action. Many countries have also reported the emergence of NPS.

5 CNB has noted an increase in the number of NPS trafficking and abuse cases detected in the last year. CNB has also completed consultations with the Health Sciences Authority, research institutes and industry stakeholders and they have indicated that there are currently no known medical and industrial uses for these substances. Given these developments and the fact that these substances mimic the effects of harmful Class A drugs, CNB has decided to list all the Fifth Schedule drugs to the First Schedule of the MDA as Class A controlled drugs.

6 Following the listing of these NPS as Class A controlled drugs, the trafficking, manufacture, import, export, possession or consumption of these substances will constitute an offence under the MDA. Any person found guilty of trafficking Class A controlled drugs

CNB NEWS RELEASE

30 Apr 2014

will face a minimum of five years' imprisonment and five strokes of the cane. They will also be liable for enhanced penalties if they re-offend or sell to young or vulnerable persons. CNB will also be empowered to subject NPS abusers to supervision, commit them to a drug rehabilitation centre (DRC) for treatment and rehabilitation, or charge them in court.

7 Mr Ng Ser Song, Director, CNB said, "The drug situation is challenging and the number of repeat drug abusers and young drug abusers remains a concern. With the abuse and trafficking of NPS on the rise, listing these new psychoactive substances as Class A controlled drugs signals our unequivocal stance that these substances are illegal and no different from other controlled drugs."

CENTRAL NARCOTICS BUREAU

30 Apr 2014

Substances Listed in Fifth Schedule of Misuse of Drugs Act, as at 30 April 2014

1. Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

{1-[(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(naphthalen-1-yl)methanone, also known as AM-1220

[1-(5-Fluoropent-1-yl)-6-nitro-1H-indol-3-yl](naphthalen-1-yl)methanone, also known as AM-1235

[1-(5-Fluoropent-1-yl)-1H-indol-3-yl](naphthalen-1-yl)methanone, also known as AM-2201

[1-(Heptan-2-yl)-2-methyl-1H-indol-3-yl](naphthalen-1-yl)methanone, also known as JWH-011

(2-Methyl-1-propyl-1H-indol-3-yl)(naphthalen-1-yl)methanone, also known as JWH-015

Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone, also known as JWH-018

(1-Hexyl-1H-indol-3-yl)(naphthalen-1-yl)methanone, also known as JWH-019

Naphthalen-1-yl[1-(pent-4-en-1-yl)-1H-indol-3-yl]methanone, also known as JWH-022

(1-Butyl-1H-indol-3-yl)(naphthalen-1-yl)methanone, also known as JWH 073

(4-Methoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone, also known as JWH-081

(4-Methylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone, also known as JWH-122

{1-[2-(Morpholin-4-yl)ethyl]-1H-indol-3-yl}(naphthalen-1-yl)methanone, also known as JWH-200

(4-Ethyl-naphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone, also known as JWH-210

(4-Chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone, also known as JWH-398

[1-(5-Fluoropent-1-yl)-1H-indol-3-yl](4-methylnaphthalen-1-yl)methanone, also known as MAM-2201

CNB NEWS RELEASE

30 Apr 2014

2. Any compound containing a 3-(1-naphthylmethyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

3-(Naphthalen-1-ylmethyl)-1-pentyl-1H-indole, also known as JWH 175

3-[(4-Methylnaphthalen-1-yl)methyl]-1-pentyl-1H-indole, also known as JWH-184

3. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

Naphthalen-1-yl(1-pentyl-1H-pyrrol-3-yl)methanone, also known as JWH-030

(1-Hexyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone, also known as JWH-031

Naphthalen-1-yl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)methanone, also known as JWH-145

(1-Hexyl-5-phenyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone, also known as JWH-147

[5-(2-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone, also known as JWH-307

Naphthalen-1-yl[5-(naphthalen-1-yl)-1-pentyl-1H-pyrrol-3-yl]methanone, also known as JWH-309

[5-(3-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone, also known as JWH-368

[5-(2-Chlorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone, also known as JWH-369

[5-(2-Methylphenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone, also known as JWH-370

CNB NEWS RELEASE

30 Apr 2014

4. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane, also known as JWH-176

5. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

2-(2-Methoxyphenyl)-1-{1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}ethanone, also known as cannabipiperidiethanone

2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone, also known as JWH-201

2-(2-Chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone, also known as JWH-203

2-(2-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone, also known as JWH-250

2-(2-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone, also known as JWH-251

2-(3-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone, also known as JWH-302

1-[1-(2-Cyclohexylethyl)-1H-indol-3-yl]-2-(2-methoxyphenyl)ethanone, also known as RCS-8

6. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not substituted in the cyclohexyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

CNB NEWS RELEASE

30 Apr 2014

2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol, also known as CP47,497

2-[5-Hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol, also known as CP55,940

7. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

[1-(5-Fluoropentyl)-1H-indol-3-yl](2-iodophenyl)methanone, also known as AM-694

(2-Iodo-5-nitrophenyl){1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone, also known as AM-1241

(2-Iodophenyl){1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone, also known as AM-2233

(4-Methoxyphenyl){2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl}methanone, also known as pravadoline

(4-Methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone, also known as RCS-4

8. Any compound containing a 3-(1-adamantoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

Adamantan-1-yl{1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone, also known as AM-1248

Adamantan-1-yl(1-pentyl-1H-indol-3-yl)methanone, also known as AB-001

9. Any compound, other than bupropion, methcathinone and 4-methylmethcathinone, that is structurally derived from 2-amino-1-phenylpropan-1-one by modification in any of the following ways:

CNB NEWS RELEASE

30 Apr 2014

- (a) substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
- (b) substitution at the 3-position with an alkyl substituent; or
- (c) substitution at the nitrogen atom with alkyl or dialkyl, benzyl or methoxybenzyl groups, or by inclusion of the nitrogen atom in a cyclic structure,

including any salt or stereoisomeric form of the above compounds, and any preparation or product containing the above compounds, for example:

2-(Dimethylamino)-1-phenylpropan-1-one, also known as metamfepramone or dimethylcathinone

1-(Fluorophenyl)-2-(methylamino)propan-1-one

2-(Methylamino)-1-phenylbutan-1-one, also known as buphedrone

1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one, also known as butylone

2-(Ethylamino)-1-phenylpropan-1-one, also known as ethcathinone

1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)propan-1-one, also known as ethylone

1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one, also known as methedrone

2-(Ethylamino)-1-(4-methylphenyl)propan-1-one, also known as 4-methylethcathinone

1-(1,3-Benzodioxol-5-yl)-2-(methylamino)propan-1-one, also known as methylone or 3,4-methylenedioxy-N-methylcathinone

1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one, also known as 3,4-methylenedioxypropylone or MDPV

1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)butan-1-one, also known as MDPBP

1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)propan-1-one, also known as MDPPP

1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)butan-1-one, also known as MPBP

1-(4-Methoxyphenyl)-2-(pyrrolidin-1-yl)propan-1-one, also known as MOPPP

2-(Methylamino)-1-phenylpentan-1-one, also known as pentedrone

1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one, also known as pentylone

1-Phenyl-2-(pyrrolidin-1-yl)butan-1-one, also known as α -PBP

1-Phenyl-2-(pyrrolidin-1-yl)propan-1-one, also known as α -PPP

1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one, also known as α -PVP

1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)pentan-1-one, also known as pyrovalerone

10. Any compound that is structurally derived from 2-aminopropan-1-one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring

CNB NEWS RELEASE

30 Apr 2014

or alkylendioxyphenyl ring system), whether or not the compound is further modified in any of the following ways:

- (a) substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
- (b) substitution at the 3-position with an alkyl substituent; or
- (c) substitution at the 2-amino nitrogen atom with alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure,

including any salt or stereoisomeric form of the above compounds, and any preparation or product containing the above compounds, for example:

1-(Naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one, also known as naphyrone or naphthylpyrovalerone

11. The following compounds, including any salt or stereoisomeric form of such compounds, and any preparation or product containing such compounds:

2,3-Dihydro-1H-inden-2-amine, also known as 2-Aminoindane

2,3-Dihydro-5-iodo-1H-inden-2-amine, also known as 5-Iodo-2-aminoindane or 5-IAI

6,7-Dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine, also known as 5,6-(methylenedioxy)-2-aminoindane or MDAI

5-(2-Aminopropyl)benzofuran, also known as 5-APB

6-(2-Aminopropyl)benzofuran, also known as 6-APB or BenzoFury

5-(2-Aminopropyl)-2,3-dihydrobenzofuran, also known as 5-APDB

6-(2-Aminopropyl)-2,3-dihydrobenzofuran, also known as 6-APDB

1-(Fluorophenyl)propan-2-amine

N-Methyl-1-(fluorophenyl)propan-2-amine

N-Methyl-1-(methylphenyl)propan-2-amine

N-Methyl-1-(methoxyphenyl)propan-2-amine

1-(4-Methylbenzo-1,3-dioxol-6-yl)propan-2-amine, also known as 5-methyl-MDA or 5-methyl-3,4-methylenedioxyamphetamine

N,N-Dimethyl-1-phenylpropan-2-amine, also known as N,N-dimethylamphetamine

[2,3-Dihydro-5-methyl-3-(morpholin-4-ylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](naphthalen-1-yl)methanone

6,6-Dimethyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1,9-diol

CNB NEWS RELEASE

30 Apr 2014

[9-Hydroxy-6-methyl-3-(5-phenylpentan-2-yl)oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate

9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol

1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-one

{4-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-yl}methanol, also known as HU-308

3-Hydroxy-2-[3-methyl-6-(2-propenyl)-cyclohex-2-en-1-yl]-5-pentyl-1,4-benzoquinone

5-[3-(1-Naphthoyl)-1H-indol-1-yl]pentanenitrile, also known as AM-2232

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, also known as UR-144

[1-(5-Fluoropent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone, also known as XLR-11 or 5-fluoro UR-144

N-(1-Adamantyl)-1-pentyl-1H-indole-3-carboxamide, also known as APICA

N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide, also known as APINACA

Naphthalen-1-yl(4-pentyloxynaphthalen-1-yl)methanone, also known as CB-13

Salvinorin A

Mitragynine

7-Hydroxymitragynine

16-Carboxymitragynine

17-O-Desmethyl-16,17-dihydromitragynine

9-O-Desmethylmitragynine

17-Carboxy-16,17-dihydromitragynine

2-Diphenylmethylpiperidine, also known as desoxypipradrol

Diphenyl(pyrrolidin-2-yl)methanol, also known as diphenylprolinol

N-Methyl-1-(thiophen-2-yl)propan-2-amine, also known as methiopropamine

2-(3-Methoxyphenyl)-2-(N-ethylamino)cyclohexanone, also known as methoxetamine

(N-Methyl-4-phenylpiperidin-4-yl)propanoate, also known as desmethylprodine

4-(Fluorophenyl)piperazine.

Substances to be Listed in Fifth Schedule of Misuse of Drugs Act, on 1 May 2014

1. The following compounds, including any salt or stereoisomeric form of such compounds, and any preparation or product containing such compounds:
 - (1) N-(1-Adamantyl)-5-fluoropentyl-1H-indazole-3-carboxamide (also known as 5-Fluoro-APINACA or 5F-AKB48)
 - (2) N-(1-Adamantyl)-5-fluoropentyl-1H-indole-3-carboxamide (also known as 5-Fluoro-APICA or STS-135)
 - (3) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as AB-FUBINACA)
 - (4) 4-(2-Aminopropyl)benzofuran (also known as 4-APB)
 - (5) 7-(2-Aminopropyl)benzofuran (also known as 7-APB)
 - (6) 4-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 4-APDB)
 - (7) 7-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 7-APDB)
 - (8) 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (also known as 25B-NBOMe)
 - (9) 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (also known as 25C-NBOMe)
 - (10) 2-(2,5-Dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25H-NBOMe)
 - (11) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (also known as 25I-NBOMe)
 - (12) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (also known as 5-Fluoro-PB-22 or 5-Fluoro-QUPIC)
 - (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (also known as PB-22 or QUPIC)